Fig. 6

CD3 depletion in NestinCre; STOPFloxc-MYC mice reduces proliferation and bulk of CPT. a A significant reduction in tumour incidence was noted in the triple compound mutant (NestinCre; STOPFlox-c-MYC;NOD-SCID) as compared to double compound mutant (NestinCre; STOPFlox-c-MYC). NODSCID mouse group confirmed no tumour development without c-MYC overexpression in an immunocompromised background. b, c Tumour area reduction, as assessed by Definiens® image analysis software in the triple compound mutant (b right) as compared to double compound mutant (b left). Representative tumour histology (b upper panel) and tumour area measured on Definiens (b lower panel, no colour). c Quantification bar graph with mean area ± SEM; n = 6 for double transgenic and n = 5 for triple transgenic; * P < 0.05. d Flow peaks showing reduction in CD3+ cells in blood following anti-CD3 injection (pre-treatment blue, post treatment red peaks). e Reduction in CD3+ population was noted post injection in the anti-CD3 treated group in comparison to pre injections. No significant changes where observed in the isotype treated group. Common Leukocyte Antigen - CD45+ CD3+ cells were selected; Circles = pre-injection levels, Squares = post injection levels after 4 weeks, each representing one mouse. Mean ± SEM represented; * P < 0.05. f Similar results were observed in spleen where a significant reduction of CD3+ cells was noted in post injection anti-CD3 cohort in comparison to isotype control; Mean ± SEM represented; ** P < 0.01. g H&E of CPT assessed by Definiens® image analysis software showed a reduced tumour area in the anti-CD3 injected cohort in comparison to isotype injected tumours. Representative tumour histology (g, upper panel) and tumour area measured on Definiens (G, lower panel, red) and quantification in (h) bar graph with mean area ± SEM; n = 9 for anti-CD3 treated and n = 8 for isotype control; * P < 0.05. i, j Reduced number of CD3+ cells (arrow head) was observed in anti-CD3 treated group (right panel) in comparison to isotype control (left panel). j Quantification bar graph of Ki67+ and CD3+ cells with mean cells/HPF ± SEM; n = 9 for anti-CD3 treated and n = 8 for isotype control; * P < 0.05; *** P < 0.001. Scale bar = 400 (G top) 200 μm (g bottom) and 50 μm (i)